dotMD.com
Find a Doctor
Health Research, In Plain English • 5,828 Stories

Medical breakthroughs, translated for real life.

Every story explains a peer-reviewed clinical trial or medical journal report at a clear, 8th-grade reading level—with 15-second takeaways, participant counts, Study Rigor Scores, and a direct link to the formal paper.

All Research Stories Phase III Randomized Trial (3,355) Randomized Controlled Trial (1,799) Meta-Analysis (566) Peer-Reviewed Journal (Clinical Trials) (39) FDA Drug Recall (Class II) (15) Completed Human Clinical Trial (NCT) (15) FDA Safety Alert (13) FDA Recall (12) Peer-Reviewed Journal (Longevity & Biotech) (8) Clinical Trial (4) Clinical Pharmacology Review (1) Systematic Review (1)
Live Journal & Safety Desks: JAMA Network New England Journal of Medicine The Lancet BMJ Recent Research Nature Medicine FDA MedWatch Safety Alerts FDA Drug Recalls
Phase III Randomized Trial • The Lancet. Haematology • 2026-11-15

Can This Approach Help? Inside the Latest Research on Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide

The addition of decitabine to BuCy conditioning reduced the risk of relapse with an acceptable safety profile in adult patients with KMT2A‑rearranged leukaemia and could be a suitable therapeutic option for this population.

Read Plain-English Story | Formal Study: “Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial”
N = 65 Rigor 82/100
Formal Study (PMID #42956759)
Phase III Randomized Trial • The Lancet. Oncology • 2026-11-15

Can This Approach Help? Inside the Latest Research on Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy

In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in.

Read Plain-English Story | Formal Study: “Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial”
N = 113 Rigor 82/100
Formal Study (PMID #42927765)
Randomized Controlled Trial • The Lancet. Oncology • 2026-11-15

Can This Approach Help? Inside the Latest Research on Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for

The risk-benefit ratio observed in the DALY 2-EU study supports consideration of zamto-cel as a second-line standard treatment option for patients with relapsed or refractory large B-cell lymphoma who are ineligible for...

Read Plain-English Story | Formal Study: “Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study”
N = 82 Rigor 82/100
Formal Study (PMID #42933440)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [World Report] First human case of Shamonda virus

A patient in France has died from the infection, which normally affects cattle. Virologists say the wider risk to public health is low. Marianne Guenot reports.

Read Plain-English Story | Formal Study: “[World Report] First human case of Shamonda virus recorded”
Rigor 97/100
Formal Study (PMID #LANCET-2806831375)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [Perspectives] Derek Griffith: transformative leader in men's

“We know a lot about male health. We don’t know a lot about men's health”, says Derek Griffith, who is one of the authors of a new Lancet Series on men's health. “Male health is about male bodies and hormones. Men's health is more holistic and comprehensive an

Read Plain-English Story | Formal Study: “[Perspectives] Derek Griffith: transformative leader in men's health”
Rigor 96/100
Formal Study (PMID #LANCET-593963419)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [Editorial] Improving men's health in a changing

Many men are failing to thrive. Shorter life expectancies for men than for woman first emerged in the 19th century and the gap has continued to widen (albeit with geographical variations). Men have a higher burden of illness: global disability-adjusted life-ye

Read Plain-English Story | Formal Study: “[Editorial] Improving men's health in a changing world”
Rigor 95/100
Formal Study (PMID #LANCET-1571222492)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [World Report] Health-care costs could help decide US midterm

With an opportunity to overturn Republican control of Congress, Democrats hope to win voters’ support by focusing on cuts to health-care programmes. Susan Jaffe reports from Washington, DC.

Read Plain-English Story | Formal Study: “[World Report] Health-care costs could help decide US midterm elections”
Rigor 94/100
Formal Study (PMID #LANCET-714342426)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [Perspectives] James W Catto: tackling the inequalities in men's

Jim Catto, co-leading author of the Lancet Series on men's health, was reluctant to be the subject of a profile, insisting it is more important to highlight what he is trying to accomplish: tackling the inequalities in men's health. The patients he cares for c

Read Plain-English Story | Formal Study: “[Perspectives] James W Catto: tackling the inequalities in men's health”
Rigor 93/100
Formal Study (PMID #LANCET-3378993681)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [Comment] Men's health: recognising and responding to the

The authors of The Lancet's Series on men's health1–3 provide a genuinely world-scale picture of the issues. Their approach links biological with social process, and emphasises intersectional perspectives. The Series papers offer valuable case studies, and a s

Read Plain-English Story | Formal Study: “[Comment] Men's health: recognising and responding to the problems”
Rigor 93/100
Formal Study (PMID #LANCET-1391205581)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [Comment] From PROSpect to the bedside: contextual and pathophysiological

Paediatric acute respiratory distress syndrome (PARDS) is a common, severe manifestation of direct or indirect lung injury in children. Management focuses on the careful implementation of lung protective strategies with high-frequency oscillatory ventilation (

Read Plain-English Story | Formal Study: “[Comment] From PROSpect to the bedside: contextual and pathophysiological considerations”
Rigor 91/100
Formal Study (PMID #LANCET-1456482412)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [Comment] Offline: Seizing new opportunities for climate and

The Lancet Countdown on health and climate change celebrated its tenth anniversary this week. The Countdown was preceded by two Lancet Commissions that sought to mobilise multiple disciplines within universities to address the climate crisis. The first Commiss

Read Plain-English Story | Formal Study: “[Comment] Offline: Seizing new opportunities for climate and health”
Rigor 90/100
Formal Study (PMID #LANCET-2839273287)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-31

Can This Approach Help? Inside the Latest Research on [Comment] Non-invasive tests in MASH: clinical practice versus

Non-invasive tests (NITs) are central to clinical decision making in metabolic dysfunction-associated steatotic liver disease, including risk stratification, treatment decisions, referral pathways, and recruitment into clinical trials.1 As pharmacological trea

Read Plain-English Story | Formal Study: “[Comment] Non-invasive tests in MASH: clinical practice versus trials”
Rigor 90/100
Formal Study (PMID #LANCET-3803036223)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-21

Can This Approach Help? Inside the Latest Research on [Comment] Preserving the uterus: an effective dual therapy to avoid

Heavy menstrual bleeding is a challenging condition that, when refractory to conventional treatment, frequently culminates in hysterectomy. Endometrial ablation offers an effective, uterus-sparing alternative for women who do not desire future childbearing, wi

Read Plain-English Story | Formal Study: “[Comment] Preserving the uterus: an effective dual therapy to avoid hysterectomy”
Rigor 95/100
Formal Study (PMID #LANCET-2824242815)
Peer-Reviewed Journal (Clinical Trials) • The Lancet • 2026-10-21

Can This Approach Help? Inside the Latest Research on [Comment] Redefining curative treatment for early-stage mismatch repair-deficient

For decades, the standard of care for patients with resected stage II and III colon cancer has centred on surgery with consideration of postoperative adjuvant systemic therapy to reduce risk of recurrence. Mismatch repair deficiency is seen in 10–15% of non-me

Read Plain-English Story | Formal Study: “[Comment] Redefining curative treatment for early-stage mismatch repair-deficient colon cancer”
Rigor 90/100
Formal Study (PMID #LANCET-668991693)
Phase III Randomized Trial • The lancet. Diabetes & endocrinology • 2025-11-15

Managing Obesity (STEP UP): Can Once-weekly semaglutide 7·2 mg Make a Real Difference? (What a 1,005-Person Study Found)

Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.

Read Plain-English Story | Formal Study: “Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial”
N = 1,005 Rigor 96/100
Formal Study (PMID #40961952)
Phase III Randomized Trial • The lancet. Diabetes & endocrinology • 2025-11-15

New Insights on Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP: What a 307-Participant Study Found

Among people with obesity and type 2 diabetes, semaglutide 7·2 mg was superior to placebo in reducing bodyweight, waist circumference, and HbA 1c .

Read Plain-English Story | Formal Study: “Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial”
N = 307 Rigor 93/100
Formal Study (PMID #40961953)
Phase III Randomized Trial • The Lancet. Rheumatology • 2025-11-15

New Insights on Serum biomarkers associated with baricitinib response in patients with juvenile: What a 220-Participant Study Found

To our knowledge, this is the first study measuring serum protein markers in the context of an intervention trial with baricitinib in patients with JIA.

Read Plain-English Story | Formal Study: “Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial”
N = 220 Rigor 88/100
Formal Study (PMID #40915298)
Phase III Randomized Trial • The lancet. Diabetes & endocrinology • 2025-10-15

Can This Approach Help? Inside the Latest Research on Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as

In this Asian population with obesity (BMI ≥25·0 kg/m 2 ), once-weekly semaglutide 2·4 mg significantly reduced bodyweight and was well tolerated.

Read Plain-English Story | Formal Study: “Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m 2 , in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial”
N = 150 Rigor 88/100
Formal Study (PMID #40825340)
Randomized Controlled Trial • The lancet. Psychiatry • 2025-07-15

Can This Approach Help? Inside the Latest Research on Benefits and safety of semaglutide versus placebo for people with schizophrenia

Semaglutide led to significantly greater weight loss than placebo in this small trial without affecting psychotic symptoms or clozapine concentrations.

Read Plain-English Story | Formal Study: “Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia”
N = 15 Rigor 88/100
Formal Study (PMID #40506208)
Phase III Randomized Trial • The lancet. Diabetes & endocrinology • 2025-07-15

New Insights on Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes: What a 646-Participant Study Found

In adults with inadequately controlled type 2 diabetes on daily basal insulin therapy, once‑weekly IcoSema showed superiority to once-weekly icodec alone in changes in HbA 1c and in overall lower rate of combined clinically...

Read Plain-English Story | Formal Study: “Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial”
N = 646 Rigor 87/100
Formal Study (PMID #40482671)
Phase III Randomized Trial • The lancet. Diabetes & endocrinology • 2025-07-15

New Insights on Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes: What a 340-Participant Study Found

Once-weekly IcoSema achieved non-inferior HbA 1c reduction and superiority in change in bodyweight, weekly total insulin dose, and hypoglycaemia rates versus daily BBT, suggesting that there is a potentially beneficial...

Read Plain-English Story | Formal Study: “Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial”
N = 340 Rigor 87/100
Formal Study (PMID #40482670)
Randomized Controlled Trial • The lancet. Diabetes & endocrinology • 2025-03-15

New Insights on Semaglutide in obesity-related heart failure with preserved ejection fraction and: What a 227-Participant Study Found

Semaglutide 2·4 mg improved heart failure-related symptoms and physical limitations, and reduced bodyweight in patients with obesity-related HFpEF and type 2 diabetes, all independently of baseline HbA 1c , and resulted in...

Read Plain-English Story | Formal Study: “Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA 1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial”
N = 227 Rigor 88/100
Formal Study (PMID #39848268)
Phase III Randomized Trial • The Lancet. Respiratory medicine • 2024-11-15

Can This Approach Help? Inside the Latest Research on Benefits and safety of gefapixant in women with chronic cough and cough-induced

Gefapixant 45 mg twice daily is the first treatment to show efficacy versus placebo in reducing CSUI episodes in participants with refractory or unexplained chronic cough.

Read Plain-English Story | Formal Study: “Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial”
N = 185 Rigor 88/100
Formal Study (PMID #39222649)
Phase III Randomized Trial • The Lancet. Neurology • 2024-10-15

Can This Approach Help? Inside the Latest Research on Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised,

We were unable to conclude that lamotrigine is non-inferior to mexiletine; however, improvements in all outcome measures from baseline were similar between lamotrigine and mexiletine.

Read Plain-English Story | Formal Study: “Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial”
N = 30 Rigor 88/100
Formal Study (PMID #39304240)
Phase III Randomized Trial • The lancet. Healthy longevity • 2024-02-15

Can This Approach Help? Inside the Latest Research on A psychosocial goal-setting and manualised support intervention for independence

To our knowledge, NIDUS-Family is the first readily scalable intervention for people with dementia and their family carers that improves attainment of personalised goals.

Read Plain-English Story | Formal Study: “A psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: a single-masked, phase 3, superiority, randomised controlled trial”
N = 163 Rigor 82/100
Formal Study (PMID #38310894)
Randomized Controlled Trial • The Lancet. Neurology • 2023-11-15

Can This Approach Help? Inside the Latest Research on Effect of blood pressure-lowering agents on microvascular function in people with

4 weeks of treatment with amlodipine, losartan, or atenolol did not differ in their effects on cerebrovascular reactivity in people with sporadic small vessel disease but did result in differential treatment effects in...

Read Plain-English Story | Formal Study: “Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial”
N = 75 Rigor 82/100
Formal Study (PMID #37863608)
Randomized Controlled Trial • The lancet. Gastroenterology & hepatology • 2023-06-15

Can This Approach Help? Inside the Latest Research on Semaglutide 2·4 mg once weekly in patients with non-alcoholic

In patients with NASH and compensated cirrhosis, semaglutide did not significantly improve fibrosis or achievement of NASH resolution versus placebo.

Read Plain-English Story | Formal Study: “Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial”
N = 71 Rigor 88/100
Formal Study (PMID #36934740)
Phase III Randomized Trial • The Lancet. Infectious diseases • 2023-03-15

New Insights on Benefits and safety of moxidectin and albendazole compared with ivermectin and: What a 771-Participant Study Found

Our findings show inferiority of moxidectin and albendazole to ivermectin and albendazole against T trichiura.

Read Plain-English Story | Formal Study: “Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2/3 trial”
N = 771 Rigor 87/100
Formal Study (PMID #36354034)
Randomized Controlled Trial • The lancet. Diabetes & endocrinology • 2022-06-15

Can This Approach Help? Inside the Latest Research on Subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet

The glycaemic efficacy of GIP/GLP-1 receptor agonist tirzepatide in type 2 diabetes results from concurrent improvements in key components of diabetes pathophysiology, namely β-cell function, insulin sensitivity, and glucagon...

Read Plain-English Story | Formal Study: “Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial”
N = 117 Rigor 88/100
Formal Study (PMID #35468322)
Phase III Randomized Trial • The Lancet. Microbe • 2022-06-15

Can This Approach Help? Inside the Latest Research on Accuracy and efficacy of pre-dengue vaccination screening for previous dengue

The OnSite IgG RDT should provide a valuable tool for screening for previous dengue infection at the point of vaccination.

Read Plain-English Story | Formal Study: “Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials”
Rigor 82/100
Formal Study (PMID #35659904)
Randomized Controlled Trial • The lancet. Gastroenterology & hepatology • 2017-12-15

Can This Approach Help? Inside the Latest Research on Liraglutide on weight, satiation, and gastric functions in obesity: a randomised,

Effects of liraglutide on weight loss are associated with delay in gastric emptying of solids; measurement of gastric emptying (eg, at 5 weeks of treatment) may be a biomarker of responsiveness and may help to select...

Read Plain-English Story | Formal Study: “Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial”
N = 40 Rigor 88/100
Formal Study (PMID #28958851)
Phase III Randomized Trial • The lancet. Diabetes & endocrinology • 2016-12-15

New Insights on Exenatide once weekly plus dapagliflozin once daily versus exenatide or: What a 695-Participant Study Found

Co-initiation of exenatide and dapagliflozin improved various glycaemic measures and heart and blood vessel risk factors in patients with type 2 diabetes inadequately controlled by metformin single-drug treatment.

Read Plain-English Story | Formal Study: “Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial”
N = 695 Rigor 93/100
Formal Study (PMID #27651331)
Randomized Controlled Trial • The lancet. Diabetes & endocrinology • 2015-03-15

New Insights on Kidney effects of atorvastatin and rosuvastatin in patients with diabetes who: What a 353-Participant Study Found

Despite high-dose rosuvastatin lowering plasma lipid concentrations to a greater extent than did high-dose atorvastatin, atorvastatin seems to have more renoprotective effects for the studied chronic kidney disease population.

Read Plain-English Story | Formal Study: “Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial”
N = 353 Rigor 93/100
Formal Study (PMID #25660356)
Phase III Randomized Trial • The lancet. Diabetes & endocrinology • 2014-09-15

New Insights on Empagliflozin and glimepiride as add-on to metformin in patients with type 2: What a 769-Participant Study Found

Empagliflozin might be an effective and a well tolerated second-line treatment option for patients with type 2 diabetes who have not achieved good glycaemic control on metformin.

Read Plain-English Story | Formal Study: “Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial”
N = 769 Rigor 93/100
Formal Study (PMID #24948511)
Phase III Randomized Trial • The lancet. Diabetes & endocrinology • 2014-04-15

New Insights on Once-weekly albiglutide versus once-daily liraglutide in patients with type 2: What a 402-Participant Study Found

Patients who received once-daily liraglutide had greater reductions in HbA1c than did those who received once-weekly albiglutide.

Read Plain-English Story | Formal Study: “Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study”
N = 402 Rigor 87/100
Formal Study (PMID #24703047)